How PDUFA dates work
A PDUFA date is the FDA’s goal date for acting on a drug or biologic application. FDA does not publish a calendar of these dates. They become public only when the sponsor announces that FDA has accepted its application. Every “PDUFA calendar” online is a collection of company press releases.
Under PDUFA VII (fiscal years 2023 to 2027), FDA’s goals are:
| Application | Standard review | Priority review |
|---|---|---|
| New molecular entity NDAs and original BLAs | 10 months from the 60-day filing date | 6 months from the 60-day filing date |
| Non-NME original NDAs | 10 months from receipt | 6 months from receipt |
FDA aims to meet these goals for 90% of applications, so a date is a target, not a promise. A major amendment late in review can extend the goal by three months. FDA can also act early. The outcome on the date is either an approval or a complete response letter (CRL) explaining what is missing.
PDUFA VII covers applications received through 30 September 2027. The next reauthorization (PDUFA VIII) may change these goals.
2026 so far: approvals, speed, and transparency
Approvals are ahead of last year. As of 20 October 2026, FDA’s CDER had approved 47 novel drugs in 2026. That already beats the full-year total for 2025.
| Year | CDER novel drug approvals |
|---|---|
| 2023 | 55 |
| 2024 | 50 |
| 2025 | 46 |
| 2026 (to 20 Oct) | 47 |
The most recent approvals were Hibsago (bepirovirsen, chronic hepatitis B, 20 Oct), Hovilpri (pritelivir, 9 Oct), Emcitate (tiratricol, 28 Sep), and Atebrioz (zilurgisertib) and Juvmo (tavapadon), both on 25 Sep.
Some approvals now come much faster. The Commissioner’s National Priority Voucher (CNPV) pilot targets a 1 to 2 month review, compared with 10 to 12 months normally. FDA’s CNPV page lists 11 approval announcements from December 2025 to 19 October 2026, including the first new molecular entity under the program (1 April 2026) and the first oral PCSK9 inhibitor (17 July 2026). A voucher can move a decision far ahead of any date a standard calendar would predict.
On-time action is less certain than it was. FDA cut staff in 2025. A secondary analysis reports that 78% of drug actions in the second half of 2025 were on time, below the historical 85 to 90%. Treat any single date as a likely window, not a fixed day.
Negative outcomes are now public. Since September 2025, FDA has published complete response letters promptly after issuing them, with redactions. When a forecast date passes without an approval, the CRL itself is often the best evidence of what went wrong.
PDUFA dates to watch
We checked these dates against the sponsor’s own announcement or a report of it:
| Target date | Drug | Sponsor | Indication | Notes |
|---|---|---|---|---|
| 14 Nov 2026 | ivonescimab plus chemotherapy | Summit Therapeutics | EGFR-mutated non-squamous NSCLC after a third-generation EGFR TKI | BLA accepted January 2026 |
| 30 Nov 2026 | povetacicept | Vertex | IgA nephropathy in adults | BLA for accelerated approval; Breakthrough Therapy |
| 22 Dec 2026 | lorundrostat | Mineralys | Uncontrolled or resistant hypertension, added to other drugs | NDA; aldosterone suppression |
| 23 Dec 2026 | anito-cel | Gilead (Arcellx) | Relapsed or refractory multiple myeloma, fourth line | CAR-T; BLA accepted |
| 10 Mar 2027 | lonvo-z (lonvoguran ziclumeran) | Intellia | Hereditary angioedema | In vivo CRISPR; Priority Review; no advisory committee planned |
Third-party calendars list many more. For example, BiopharmaWatch (20 October 2026) lists target dates for:
- venglustat (type 3 Gaucher disease)
- neladalkib (ALK-positive NSCLC)
- relutrigine (SCN2A and SCN8A epilepsy)
- Yeztugo tablets (HIV PrEP)
- tinlarebant (Stargardt disease)
We did not confirm these with each sponsor, so check the company release before relying on them.
Keep in mind:
- Weekend dates usually mean action on the prior business day.
- Some calendar entries are estimates or a quarter, not a fixed date.
- A voucher, a major amendment, or a CRL can change any of these.
Using approval forecasts in AI and RAG
- Index the sponsor’s press release or SEC filing. Use calendar sites only to find dates.
- Store each date with its source, retrieval date, and review type (standard, priority, or voucher).
- Link outcomes. After the date, attach the FDA approval or the published CRL to the same record.
- Separate what is known from what is estimated. Label quarter windows and estimates as such.
- Re-check weekly. Extensions and early actions are common.
Common mistakes
- Treating a PDUFA date as a guaranteed approval date.
- Citing an aggregator without checking the company release.
- Missing a three-month extension after a major amendment.
- Forgetting that a voucher can bring a decision months forward.
- Ignoring published CRLs when a date passes.
Checklist
- Each date traced to a sponsor disclosure
- Review type and application type recorded
- Retrieval date stored
- Outcome (approval or CRL) linked after the date
- Weekly re-check scheduled
How AskDona helps
AskDona checks your regulatory tracker against the press releases, FDA letters, and filings you load. It flags any date that has no source, and shows the passage behind each date and outcome.
Run a sample PDUFA tracker evidence check
AskDona shows the evidence; your regulatory and launch teams decide.
Editor’s note. This article is general information, not investment, legal, or regulatory advice. Dates come from sponsor disclosures and third-party calendars as of 29 October 2026 and can change at any time.
FAQ
Does FDA publish a PDUFA calendar? No. PDUFA dates become public when sponsors announce them.
How many novel drugs has FDA approved in 2026? CDER had approved 47 novel drugs as of 20 October 2026, more than the 46 approved in all of 2025.
What is a national priority voucher? It is a voucher under an FDA pilot program, the Commissioner’s National Priority Voucher (CNPV). The program aims to cut review to 1 to 2 months.
What happens if a drug is not approved on its PDUFA date? FDA usually issues a complete response letter, and FDA now publishes these promptly.
References
All pages opened and checked by October 29, 2026.
| Source | What it supports |
|---|---|
| FDA: Novel Drug Approvals for 2026 | 47 approvals, latest approvals |
| FDA: PDUFA VII commitment letter (PDF) | Review goals, FY2023 to 2027 |
| FDA: CNPV pilot program | 1 to 2 month target, approvals list |
| Pharma Manufacturing: FDA to publish CRLs (Sep 2025) | Prompt CRL publication |
| IntuitionLabs: 2026 novel drug tracker | 2023 to 2025 counts, on-time rate analysis |
| PharmaShots: Summit ivonescimab BLA | 14 Nov 2026 date |
| Vertex via BioSpace: povetacicept BLA | 30 Nov 2026 date |
| PharmaNow: Mineralys lorundrostat NDA | 22 Dec 2026 date |
| Arcellx 8-K exhibit (SEC) | Anito-cel, 23 Dec 2026 |
| Intellia: lonvo-z BLA accepted | 10 Mar 2027 date |
| BiopharmaWatch: FDA calendar Q4 2026 | Other listed dates |